David Tuveson
Cold Spring Harbor Laboratory, New York, USA
David Tuveson is Director of the NCI-designated Cancer Center at the Cold Spring Harbor Laboratory, and the Roy J. Zuckerberg Professor of Cancer Research. Dr. Tuveson was the 2021-2022 President of the American Association for Cancer Research, and is the Chief Scientist of the Lustgarten Foundation for Pancreatic Cancer Research. Dr. Tuveson obtained a bachelors degree in chemistry at M.I.T., followed by M.D. and Ph.D. degrees at Johns Hopkins. Dr. Tuveson was a medical resident at Brigham and Women’s Hospital and a medical oncology fellow at Dana-Farber/Harvard Cancer Center. During his post-doctoral years in Boston, Dr. Tuveson co-developed KIT inhibitors for gastrointestinal stromal tumors with George Demetri. Simultaneously, he generated several widely-used mouse cancer models with Tyler Jacks. As an independent investigator, his lab developed the first mouse models of ductal pancreatic cancer at the University of Pennsylvania. Subsequently, Dr. Tuveson was recruited to the University of Cambridge where his lab identified poor drug delivery as a barrier for therapeutic efficacy in pancreatic cancer. He was then recruited to CSHL as the Deputy Director of the Cancer Center and to serve as Director of Research for the Lustgarten Foundation. At CSHL, his lab co-developed pancreatic organoid cancer models with Hans Clevers, and made a series of observations regarding cancer fibroblasts, redox regulation, pancreatitis, and the Ras pathway. His awards include the Rita Allen Scholarship, the Jan Waldenström Award and the Hamdan Award. Dr. Tuveson is an elected Fellow of the AACR Academy, the ASCI, AAP, and a Member of the National Academy of Medicine (USA).
David Tuveson is Director of the NCI-designated Cancer Center at the Cold Spring Harbor Laboratory, and the Roy J. Zuckerberg Professor of Cancer Research. Dr. Tuveson was the 2021-2022 President of the American Association for Cancer Research, and is the Chief Scientist of the Lustgarten Foundation for Pancreatic Cancer Research. Dr. Tuveson obtained a bachelors degree in chemistry at M.I.T., followed by M.D. and Ph.D. degrees at Johns Hopkins. Dr. Tuveson was a medical resident at Brigham and Women’s Hospital and a medical oncology fellow at Dana-Farber/Harvard Cancer Center. During his post-doctoral years in Boston, Dr. Tuveson co-developed KIT inhibitors for gastrointestinal stromal tumors with George Demetri. Simultaneously, he generated several widely-used mouse cancer models with Tyler Jacks. As an independent investigator, his lab developed the first mouse models of ductal pancreatic cancer at the University of Pennsylvania. Subsequently, Dr. Tuveson was recruited to the University of Cambridge where his lab identified poor drug delivery as a barrier for therapeutic efficacy in pancreatic cancer. He was then recruited to CSHL as the Deputy Director of the Cancer Center and to serve as Director of Research for the Lustgarten Foundation. At CSHL, his lab co-developed pancreatic organoid cancer models with Hans Clevers, and made a series of observations regarding cancer fibroblasts, redox regulation, pancreatitis, and the Ras pathway. His awards include the Rita Allen Scholarship, the Jan Waldenström Award and the Hamdan Award. Dr. Tuveson is an elected Fellow of the AACR Academy, the ASCI, AAP, and a Member of the National Academy of Medicine (USA).
